布洛芬基础上加用对乙酰氨基酚或阿片类药物用于儿童肌肉骨骼损伤:两项随机临床试验
两项随机、双盲、安慰剂对照试验于2019年4月至2023年3月在6所加拿大大学附属三级儿童急诊科开展,纳入6至17岁、非手术性急性肢体损伤(<24小时)且口头数字评分量表(vNRS)疼痛评分≥5/10的儿童。阿片试验随机分为布洛芬+氢吗啡酮、布洛芬+对乙酰氨基酚或布洛芬单药;非阿片试验随机分为布洛芬+对乙酰氨基酚或布洛芬单药,均为单次口服给药,布洛芬10 mg/kg(最大600 mg),对乙酰氨基酚15 mg/kg(最大1000 mg),氢吗啡酮0.05 mg/kg(最大5 mg)。合并分析显示给药后60分钟vNRS评分三组分别为4.8、4.6、4.6(P=.78),无差异;氢吗啡酮组任何不良事件发生率28.2%,高于对乙酰氨基酚组6.1%和布洛芬单药组5.8%,无严重不良事件。
要点
- 儿童急性非手术性肢体损伤(<24小时)且vNRS≥5/10,布洛芬+对乙酰氨基酚与布洛芬单药60分钟vNRS评分分别为4.6 vs 4.6(P=.78),未改善疼痛。
- 布洛芬+氢吗啡酮组60分钟vNRS评分为4.8,与布洛芬单药组4.6相比无差异(P=.78)。
- 氢吗啡酮组任何不良事件发生率28.2%,约为对乙酰氨基酚组6.1%和布洛芬单药组5.8%的4倍,无严重不良事件。
- 布洛芬剂量为10 mg/kg(最大600 mg),对乙酰氨基酚15 mg/kg(最大1000 mg),氢吗啡酮0.05 mg/kg(最大5 mg),均为单次口服。
- 作者结论:对于此类患儿,布洛芬加对乙酰氨基酚或加氢吗啡酮相比布洛芬单药均未在60分钟改善疼痛评分。
适用人群与场景
- 6至17岁儿童,因非手术性急性肢体损伤就诊于加拿大6所大学附属三级儿童急诊科,损伤时间<24小时,且vNRS疼痛评分≥5/10(0为无痛,10为最痛)。
诊断标准与关键阈值
- 采用口头数字评分量表(vNRS)评估疼痛,评分范围0(无痛)至10(最痛),最小临床重要差异为1.5。
- 纳入标准:非手术性急性肢体损伤<24小时,vNRS评分≥5/10。
处置流程与药物剂量
- 布洛芬单次口服10 mg/kg(最大600 mg)。
- 对乙酰氨基酚单次口服15 mg/kg(最大1000 mg),与布洛芬联用。
- 氢吗啡酮单次口服0.05 mg/kg(最大5 mg),与布洛芬联用。
- 主要疗效终点为给药后60分钟自我报告的vNRS疼痛评分。
研究设计与关键结果
- 两项随机、双盲、安慰剂对照试验,2019年4月至2023年3月在6所加拿大大学附属三级儿童急诊科开展;筛查8098名儿童,随机699名,653名纳入疗效分析。
- 阿片试验纳入249名儿童:布洛芬+氢吗啡酮组110名,布洛芬+对乙酰氨基酚组70名,布洛芬单药组69名。
- 非阿片试验纳入450名儿童:布洛芬+对乙酰氨基酚组225名,布洛芬单药组225名。
- 两试验总体平均(SD)年龄11.5(3.5)岁,47.4%为女性;入组时平均(SD)vNRS评分为6.4(1.8)。
- 合并分析显示给药后60分钟平均(SD)vNRS评分:布洛芬+氢吗啡酮组4.8(2.6),布洛芬+对乙酰氨基酚组4.6(2.4),布洛芬单药组4.6(2.3)(P=.78)。
- 任何不良事件发生率:布洛芬+氢吗啡酮组28.2%,布洛芬+对乙酰氨基酚组6.1%,布洛芬单药组5.8%;无严重不良事件。
证据类型、等级与局限
- 证据类型:两项随机、双盲、安慰剂对照临床试验。
- 试验注册号:Clinicaltrials.gov NCT03767933。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:对于急性非手术性肌肉骨骼损伤的儿童,布洛芬加对乙酰氨基酚或布洛芬加氢吗啡酮相比布洛芬单药,给药后60分钟疼痛评分未改善。
- 氢吗啡酮组不良事件发生率约4倍于对乙酰氨基酚组或布洛芬单药组(28.2% vs 6.1% vs 5.8%)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Ibuprofen is first-line therapy for musculoskeletal pain. However, two-thirds of children experience inadequate pain relief with ibuprofen monotherapy, and the efficacy of additive medications for moderate to severe musculoskeletal pain is unclear.
OBJECTIVE: To determine whether treatment with an opioid (hydromorphone) plus ibuprofen or nonopioid (acetaminophen [paracetamol]) plus ibuprofen decreased pain scores compared with ibuprofen alone.
DESIGN, SETTING, AND PARTICIPANTS: Two randomized, double-masked, placebo-controlled trials were conducted from April 2019 to March 2023 in 6 university-affiliated, tertiary care Canadian pediatric emergency departments. Children aged 6 to 17 years presenting with a nonoperative acute limb injury (<24 hours) and a verbal numerical rating scale (vNRS) pain score of 5 or more out of 10 were enrolled. Date of final follow-up was March 22, 2023.
INTERVENTIONS: The opioid trial randomized participants to a single oral dose of ibuprofen plus hydromorphone, ibuprofen plus acetaminophen, or ibuprofen alone. The nonopioid trial randomized participants to a single oral dose of ibuprofen plus acetaminophen or ibuprofen alone. In all groups, ibuprofen was dosed at 10 mg/kg (maximum, 600 mg). The acetaminophen dose was 15 mg/kg (maximum, 1000 mg), and the hydromorphone dose was 0.05 mg/kg (maximum, 5 mg).
MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was self-reported vNRS pain score at 60 minutes post medication administration (score range, 0 [no pain] to 10 [worst pain]; minimal clinically important difference, 1.5). The primary safety end point was the proportion of children with any adverse event related to study drug administration.
RESULTS: A total of 8098 children were screened for eligibility; 699 were randomized and 653 were included in the efficacy analyses. The opioid trial included 249 children: 110 randomized to ibuprofen plus hydromorphone, 70 to ibuprofen plus acetaminophen, and 69 to ibuprofen alone. The nonopioid trial included 450 children: 225 randomized to a single oral dose of ibuprofen plus acetaminophen and 225 randomized to ibuprofen alone. The mean (SD) age of children in the 2 trials was 11.5 (3.5) years and 47.4% were female. The mean (SD) vNRS score at recruitment was 6.4 (1.8). In pooled analyses, mean (SD) vNRS scores 60 minutes after drug administration were 4.8 (2.6) in the ibuprofen plus hydromorphone group, 4.6 (2.4) in the ibuprofen plus acetaminophen group, and 4.6 (2.3) in the ibuprofen alone group (P = .78). Any adverse event occurred at higher rates in the ibuprofen plus hydromorphone group (28.2%) compared with the ibuprofen plus acetaminophen (6.1%) or ibuprofen alone groups (5.8%). No serious adverse events occurred.
CONCLUSIONS AND RELEVANCE: For children with acute nonoperative musculoskeletal injury, pain scores at 60 minutes after drug administration did not improve with ibuprofen plus acetaminophen or ibuprofen plus hydromorphone compared with ibuprofen alone. Adverse events were 4-fold more frequent with hydromorphone.
TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT03767933.
参考来源
- Ali S, Klassen TP, Candelaria P, et al. Acetaminophen (Paracetamol) or Opioid Analgesia Added to Ibuprofen for Children's Musculoskeletal Injury: Two Randomized Clinical Trials. JAMA. 2026. PMID: 41505155. doi:10.1001/jama.2025.25033
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。